MK0767 in Type 2 Diabetes (0767-012)

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00543556

Enrollment

514

Registered

2007-10-15

Start date

2001-10-31

Completion date

2003-11-30

Last updated

2015-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

This is a clinical trial in patients with Type 2 Diabetes to test the safety of MK0767. This study will also see how effective MK0767 is in lowering markers of glucose metabolism and improving the lipid profile and non-HDL cholesterol when compared with placebo and pioglitazone.

Interventions

DRUGMK0767

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

21 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Type 2 Diabetes Mellitus patients between the ages of 21 and 75 inclusive * Patient is willing to discontinue current therapy for the duration of the study * Patient is not a heavy drinker

Exclusion criteria

* Patient has a history of Type 1 diabetes and/or ketoacidosis * Patient has severe diabetic retinopathy, or nephropathy, or neuropath * Patient has has anti-hyperglycemic therapy including insulin, or rosiglitazone and pioglitazone or 2 or more oral agents in combination within 8 weeks prior to visit 1 * Patient has a history of, allergy to, intolerance or hypersensitive to troglitazone, rosiglitazone, or pioglitazone including history of elevated liver function test, jaundice, or hepatotoxicity associated with these treatments

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026